Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment

Purpose: Cervical cancer cells are addicted to the expression of the human papillomavirus (HPV) oncoproteins E6 and E7. The oncogencity of E6 is mediated in part by targeting p53 and PDZ-family tumor suppressor proteins for rapid proteasomal degradation, whereas the E7 oncoprotein acts in part by coopting histone deacetylases (HDAC)1/2. Here, we examine the hypothesis that inhibition of proteasome function and HDAC activity would synergistically and specifically trigger cervical cancer cell death by the interruption of E6 and E7 signaling. Experimental Design: The sensitivity and molecular responses of keratinocytes and HPV-positive and HPV-negative cervical cancer cells and xenografts to combinations of proteasome and HDAC inhibitors were tested. The expression of HDAC1/HDAC2 in situ was examined in cervical cancer, its precursors, and normal epithelium. Results: Cervical cancer cell lines exhibit greater sensitivity to proteasome inhibitors than do HPV-negative cervical cancers or primary human keratinocytes. Treatment of cervical cancer cells with bortezomib elevated the level of p53 but not hDlg, hScribble or hMAGI. Immunohistochemical analysis revealed elevated HDAC1/HDAC2 expression in cervical dysplasia and cervical carcinoma versus normal cervical epithelium. The combination of bortezomib and HDAC inhibitor trichostatin A or vorinostat shows synergistic killing of HPV-positive, but not HPV-negative, cervical cancer cell lines. Similarly, treatment of HeLa xenografts with the combination of bortezomib and trichostatin A retarded tumor growth significantly more effectively than either agent alone. Conclusions: A combination of proteasome and HDAC inhibitors, including bortezomib and vorinostat, respectively, warrants exploration for the treatment of cervical cancer.

[1]  Kwun Chuen Gary Chan,et al.  Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor , 2008, Clinical Cancer Research.

[2]  H. Kwon,et al.  Inhibition of histone deacetylase1 induces autophagy. , 2008, Biochemical and biophysical research communications.

[3]  H. Pitot,et al.  p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. , 2008, Cancer research.

[4]  L. Banks,et al.  HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background , 2008, Oncogene.

[5]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[6]  Kwun Chuen Gary Chan,et al.  Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC 6 Inhibitor , 2008 .

[7]  J. Taylor,et al.  HDAC6 at the Intersection of Autophagy, the Ubiquitin-proteasome System, and Neurodegeneration , 2007, Autophagy.

[8]  T. Yao,et al.  HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. , 2007, Genes & development.

[9]  T. Libermann,et al.  Human Papillomavirus Type 16 E7 Oncoprotein Associates with the Cullin 2 Ubiquitin Ligase Complex, Which Contributes to Degradation of the Retinoblastoma Tumor Suppressor , 2007, Journal of Virology.

[10]  Dan Garza,et al.  HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS , 2007, Nature.

[11]  M. Ferrarini,et al.  Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. , 2007, Blood.

[12]  M. Scheffner,et al.  The Role of the Ubiquitin Ligase E6-AP in Human Papillomavirus E6-mediated Degradation of PDZ Domain-containing Proteins* , 2007, Journal of Biological Chemistry.

[13]  D. DiMaio,et al.  Human Papillomavirus E7 Repression in Cervical Carcinoma Cells Initiates a Transcriptional Cascade Driven by the Retinoblastoma Family, Resulting in Senescence , 2006, Journal of Virology.

[14]  R. Roden,et al.  How will HPV vaccines affect cervical cancer? , 2006, Nature Reviews Cancer.

[15]  I. Shih,et al.  Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. , 2006, Cancer research.

[16]  M. Pino,et al.  Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. , 2006, Cancer research.

[17]  D. Ribatti,et al.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.

[18]  R. Kopito,et al.  HDAC6 and Microtubules Are Required for Autophagic Degradation of Aggregated Huntingtin* , 2005, Journal of Biological Chemistry.

[19]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[20]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Laimins,et al.  HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs , 2005, The EMBO journal.

[22]  K. Anderson,et al.  Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib , 2005, Nature Methods.

[23]  M. Grace,et al.  Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.

[24]  Miranda Thomas,et al.  HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation , 2004, Oncogene.

[25]  M. Salto‐Tellez,et al.  50 Inhibition of histone deacetylase 2 increases apoptosis and P21 expression , 2004 .

[26]  F. Rösl,et al.  HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F–p73 pathway , 2004, Oncogene.

[27]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[28]  D. DiMaio,et al.  Repression of the Human Papillomavirus E6 Gene Initiates p53-Dependent, Telomerase-Independent Senescence and Apoptosis in HeLa Cervical Carcinoma Cells , 2004, Journal of Virology.

[29]  L. Laimins,et al.  The Binding of Histone Deacetylases and the Integrity of Zinc Finger-Like Motifs of the E7 Protein Are Essential for the Life Cycle of Human Papillomavirus Type 31 , 2004, Journal of Virology.

[30]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[31]  K. Glaser,et al.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[32]  R. Eisenman,et al.  Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[34]  K. Wada,et al.  [The ubiquitin-proteasome system and neurodegeneration]. , 2001, Rinsho shinkeigaku = Clinical neurology.

[35]  M. Guenther,et al.  The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3 , 2001, Molecular and Cellular Biology.

[36]  H. Hausen,et al.  Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression , 2001, Oncogene.

[37]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[38]  D. DiMaio,et al.  Rapid induction of senescence in human cervical carcinoma cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[40]  Andrew J. Bannister,et al.  The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth , 1999, The EMBO journal.

[41]  Tony Kouzarides,et al.  Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.

[42]  Stuart L Schreiber,et al.  Histone Deacetylase Activity Is Required for Full Transcriptional Repression by mSin3A , 1997, Cell.

[43]  S G Machado,et al.  A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. , 1994, Statistics in medicine.

[44]  C. Woodworth,et al.  Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[45]  M. Scheffner,et al.  Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53 , 1993, Molecular and cellular biology.

[46]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[47]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[48]  D. Lowy,et al.  HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. , 1989, The EMBO journal.

[49]  K. Münger,et al.  Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. , 1989, The EMBO journal.

[50]  K. Münger,et al.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.

[51]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.